Is this your firm? Get featured or correct your listing →
At a glance
Nextech Invest appears in 2 funding rounds tracked by ValueAddVC since 2026, leading 1. Its most recent tracked deal was Khartis Therapeutics' $50M Series B round (Aug 13, 2026).
Strategy
Recent changes
- Aug 13, 2026Aug 13, 2026Invested in Khartis Therapeutics (Series B, $50M) Axios
- Jun 30, 2026Jun 30, 2026Invested in Flare Therapeutics (Series C, $85M) GlobeNewswire
Portfolio
4 totalRecent Investment Activity
2Track record: led 1 and participated in 1 of 2 tracked venture rounds · 2 in the last 12 months · led 1 Series C
| Date | Company | Event | Role | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | Khartis Therapeutics | Series B | Participated | $50M | — | Foresite CapitalunverifiedLilly Asia VenturesunverifiedNextech InvestunverifiedForge Life Science Partners | Pulse story |
| Jun 30, 2026 | Flare Therapeutics | Series C | Led | $85M | — | Pulse story |
Sector / Stage Activity
Co-Investors
12Similar Firms
overlapping sector, stage or regionLatest Pulse
- Aug 13, 2026Khartis Emerges From Stealth With $95M for a Thyroid PillKhartis Therapeutics emerged from stealth with $95 million in total funding, including a new $50 million Series B, to develop an oral alternative to injectable treatments for thyroid eye disease.→
- Jul 2, 2026Crunchbase: The Week's 10 Biggest Funding Rounds, Led by Joulent's $1.75B Energy RaiseCrunchbase News' roundup of the week's 10 biggest funding rounds (June 27-July 2) was led by Houston-based energy infrastructure provider Joulent's $1.75 billion raise from National Grid Ventures, aimed squarely at AI and compute-intensive industries' power needs. Together AI's $800M Series C and Venice AI's $65M unicorn round both placed inside the top 10, alongside biotech, legal-tech, sports and video-AI rounds spanning a genuinely broad set of categories beyond pure frontier-model AI.→
- Jun 30, 2026Flare Therapeutics Raises $85M, Names New CEOFlare Therapeutics closed an $85 million insider-led Series C and named Anna Protopapas CEO, funding its first-in-class ARON-targeting degrader for prostate cancer toward a Phase 1A trial expected in Q3 2026.→
Nextech Invest FAQ
What companies has Nextech Invest invested in?
Nextech Invest's portfolio includes Khartis Therapeutics, Attovia Therapeutics, Flare Therapeutics, Parabilis Medicines.
Who does Nextech Invest co-invest with most?
In the rounds Value Add tracks, Nextech Invest most often invests alongside venBio Partners (2 shared deals), ARCH Venture Partners (1 shared deal), Boxer Capital (1 shared deal), Casdin Capital (1 shared deal), Deep Track Capital (1 shared deal).
Sources & methodologyshow
- GlobeNewswireprimary source1 fact
- Axiosmajor outlet1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.